Data from Efficacy and safety of stereotactic body radiotherapy combined with Camrelizumab and Apatinib in hepatocellular carcinoma patients with portal vein tumor thrombus

• DOI: 10.1158/1078-0432.c.6879420.v2
• Publication Date: 2024-09-16T13:00:50Z
• Authors: Yue Hu; Min Zhou; Jing Tang; Shuang Li; Hongli Liu; Jianli Hu; Hong Ma; Junli Liu; Tingting Qin; Xiongjie Yu; Yongshun Chen; Jin Peng; Yanmei Zou; Tao Zhang; Jun Xue
• Keywords: Apatinib

<div>Abstract<p>Purpose: This study aimed to evaluate the efficacy and safety of camrelizumab plus apatinib with or without stereotactic body radiotherapy (SBRT) as first-line therapy for hepatocellular carcinoma (HCC) patients portal vein tumor thrombus (PVTT). Patients Methods: is a multicenter, open-label, non-comparative, randomized trial that recruited HCC type II/III/IV PVTT, who had not previously received systemic therapy. were randomly assigned (2:1) receive (200 mg, Q3W) (250 QD) SBRT (95% PTV, 36 - 40 Gy/6 8 Gy). The primary endpoint was overall survival (OS), secondary endpoints progression-free (PFS), objective response rate (ORR), disease control (DCR), duration (DOR), time progression (TTP) safety. Results: Sixty enrolled two prospective cohorts. Median OS 12.7 months CI, 10.2-NA) 8.6 5.6-NA), median PFS 4.6 3.3-7.0) 2.5 2.0-7.6) non-SBRT cohorts, respectively. ORR DCR 47.5% 72.5% in cohort, 20.0% 40.0% cohort. most common treatment-related adverse events any grade hypertension (55.0%), hand-foot syndrome (51.7%), leukopenia (50.0%). Grade ≥ 3 reported 13 (21.7%) patients. Conclusion: First-line treatment camrelizumab-apatinib combined showed clinical benefits an acceptable profile. Thus, these combination regimens may be potential options such patients.</p></div>